Company intelligence / Profile preview

MarvelBiome, Inc.

Woburn, Massachusetts, United Statesmarvelbiome.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

MarvelBiome’s lead drug candidate has successfully completed a Phase 1 study with plans to enter Phase 2 trials for a neurodegenerative indication in mid–2025. The company also has preclinical programs targeting additional indications using its proprietary microbiome-based therapeutic platforms.

Therapeutic areas: OtherRare DiseasesNeurology
Modalities: Live biotherapeutics (microbiome-based therapeutics)microbiome compositions and metabolites
Industry: Biotech

Partnerships

Works with CDMOs for GMP manufacturing of live biotherapeutics; no major pharma partnerships disclosed as of now.

Beyond the preview

Go deeper on MarvelBiome, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MarvelBiome, Inc..

Explore the full profile